The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

The FDA approved Johnson & Johnson's Spravato, a ketamine-based nasal spray, to treat adults with major depressive disorder ...

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...

The US FDA has approved the first of its kind ketamine-based nasal spray which is supposed to act as a standalone therapy for ...

The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.